Back to Market返回行情

SGP SpyGlass Pharma, Inc. Common Stock

USHealthcare
$22.52+12.21%ClosedMarket Cap: $752.9M

As of 2026-07-10 16:00

Why SGP matters now

SpyGlass Pharma, Inc. Common Stock (SGP) is a US stock in Healthcare. The latest InvestLog snapshot shows $22.52 with +12.21% on the session and $752.9M in market capitalization; recent performance reads 1-month -11.79% and YTD -29.17%.

The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-13.8M, and EPS of $-0.69. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.8%.

The latest indexable market news headline is "SpyGlass Pharma Appoints Shannon Treviño as General Counsel" from GlobeNewsWire.

Additional event context on this page matters because analyst consensus is Buy with a median target of $62.00. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

1.49

P/S

0.00

EV/EBITDA

-15.01

DCF Value

$2.77

FCF Yield

-3.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-123.5%

ROA

-10.2%

ROIC

-11.5%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$0.00$-13.8M$-0.69
Q4 2025$0.00$-12.6M$-0.38
FY 2025$0.00$-39.9M$-1.19

Analyst Ratings

Consensus

Buy

Target (Consensus)

$62.00

Target (Median)

$62.00

Target Range

$62.00 - $62.00

Strong Buy: 0Buy: 5Hold: 0Sell: 0Strong Sell: 0

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

-0.34

SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.